CA2011654A1 - Recombinant poxvirus host range selection system - Google Patents
Recombinant poxvirus host range selection systemInfo
- Publication number
- CA2011654A1 CA2011654A1 CA2011654A CA2011654A CA2011654A1 CA 2011654 A1 CA2011654 A1 CA 2011654A1 CA 2011654 A CA2011654 A CA 2011654A CA 2011654 A CA2011654 A CA 2011654A CA 2011654 A1 CA2011654 A1 CA 2011654A1
- Authority
- CA
- Canada
- Prior art keywords
- host
- virus
- recombinant
- selection system
- deletion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000700605 Viruses Species 0.000 abstract 6
- 108090000623 proteins and genes Proteins 0.000 abstract 5
- 210000004027 cell Anatomy 0.000 abstract 4
- 238000012217 deletion Methods 0.000 abstract 3
- 230000037430 deletion Effects 0.000 abstract 3
- 230000010076 replication Effects 0.000 abstract 3
- 108700026244 Open Reading Frames Proteins 0.000 abstract 2
- 241000700618 Vaccinia virus Species 0.000 abstract 2
- 238000010367 cloning Methods 0.000 abstract 2
- 229960005486 vaccine Drugs 0.000 abstract 2
- 241000282693 Cercopithecidae Species 0.000 abstract 1
- 210000003837 chick embryo Anatomy 0.000 abstract 1
- 230000002950 deficient Effects 0.000 abstract 1
- 210000002950 fibroblast Anatomy 0.000 abstract 1
- 210000005260 human cell Anatomy 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 238000003780 insertion Methods 0.000 abstract 1
- 230000037431 insertion Effects 0.000 abstract 1
- 231100000518 lethal Toxicity 0.000 abstract 1
- 230000001665 lethal effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000013612 plasmid Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20111—Lyssavirus, e.g. rabies virus
- C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Abstract
What is described is a modified recombinant virus for expressing a gene product in a host. The modified recombinant virus has host range genes deleted therefrom so that the virus has restricted replication in the host. The modified recombinant virus also contains DNA which codes for and expresses the gene product in the host even with restricted replication of the virus in the host. The modified recombinant virus is used in a method for expressing a gene product in a host or in a cell cultured in vitro, and in a vaccine for inducing an immunological response in a host inoculated with the vaccine. What is also described is a selection system for the cloning and expression of open reading frames in poxviruses, particularly vaccinia virus. The selection system is based on a conditional lethal mutant (host range) of poxviruses.
A deletion/recombinant mutant of the vaccinia virus was generated which is capable of plaquing on primary chick embryo fibroblasts and two monkey cell lines (BSC-40 or VERO) but is defective in replication in the human cell line MRC-5. Insertion of the host range gene into the deletion/recombinant restores the ability for growth on MRC-5 cells. A series of plasmids were constructed which allow for the rapid single-step cloning and expression of any open reading frame when recombined with the deletion/recombinant and scored for growth on MRC-5 cells.
A deletion/recombinant mutant of the vaccinia virus was generated which is capable of plaquing on primary chick embryo fibroblasts and two monkey cell lines (BSC-40 or VERO) but is defective in replication in the human cell line MRC-5. Insertion of the host range gene into the deletion/recombinant restores the ability for growth on MRC-5 cells. A series of plasmids were constructed which allow for the rapid single-step cloning and expression of any open reading frame when recombined with the deletion/recombinant and scored for growth on MRC-5 cells.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/320,471 US5155020A (en) | 1989-03-08 | 1989-03-08 | Recombinant poxvirus host range selection system |
US47817990A | 1990-02-14 | 1990-02-14 | |
US320,471 | 1990-02-14 | ||
USC.I.P.478,179 | 1990-02-14 |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2011654A1 true CA2011654A1 (en) | 1990-09-08 |
CA2011654C CA2011654C (en) | 1995-12-19 |
Family
ID=26982509
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002011654A Expired - Fee Related CA2011654C (en) | 1989-03-08 | 1990-03-07 | Recombinant poxvirus host range selection system |
Country Status (15)
Country | Link |
---|---|
US (1) | US5453364A (en) |
JP (1) | JP3044062B2 (en) |
AT (1) | AT400955B (en) |
AU (1) | AU625584B2 (en) |
BE (1) | BE1004212A5 (en) |
CA (1) | CA2011654C (en) |
CH (1) | CH682669A5 (en) |
DE (1) | DE4090351T1 (en) |
DK (1) | DK157091A (en) |
GB (1) | GB2245272B (en) |
IE (1) | IE62441B1 (en) |
IT (1) | IT1239987B (en) |
LU (1) | LU88000A1 (en) |
NL (1) | NL9020389A (en) |
WO (1) | WO1990010693A1 (en) |
Families Citing this family (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5505941A (en) * | 1981-12-24 | 1996-04-09 | Health Research, Inc. | Recombinant avipox virus and method to induce an immune response |
US7767449B1 (en) | 1981-12-24 | 2010-08-03 | Health Research Incorporated | Methods using modified vaccinia virus |
US5364773A (en) * | 1991-03-07 | 1994-11-15 | Virogenetics Corporation | Genetically engineered vaccine strain |
US5174993A (en) * | 1981-12-24 | 1992-12-29 | Health Research Inc. | Recombinant avipox virus and immunological use thereof |
US5833975A (en) | 1989-03-08 | 1998-11-10 | Virogenetics Corporation | Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence |
DE10399031I1 (en) * | 1987-08-28 | 2004-01-29 | Health Research Inc | Recombinant viruses. |
US7374768B1 (en) | 1990-09-25 | 2008-05-20 | Xenova Research Limited | Viral vaccines |
US5837261A (en) * | 1990-09-25 | 1998-11-17 | Cantab Pharmaceuticals Research Limited | Viral vaccines |
BR9106879A (en) | 1990-09-25 | 1993-07-20 | Cantab Pharma Res | MUTUANT NON RETROVIRAL VIRUS, USE OF THE SAME, VACCINE AND PROCESS OF MANUFACTURING MUTANT UMVIRUS |
US5665362A (en) * | 1990-09-25 | 1997-09-09 | Cantab Pharmaceuticals Research Limited | Viral vaccines |
AU699903B2 (en) * | 1990-11-20 | 1998-12-17 | Virogenetics Corporation | Measles virus recombinant poxvirus vaccine |
US5756102A (en) * | 1990-11-20 | 1998-05-26 | Virogenetics Corporation | Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants |
US6309647B1 (en) | 1999-07-15 | 2001-10-30 | Aventis Pasteur | Poxvirus—canine dispemper virus (CDV) or measles virus recombinants and compositions and methods employing the recombinants |
EP0575491B1 (en) * | 1991-03-07 | 2003-08-13 | Virogenetics Corporation | Genetically engineered vaccine strain |
US5766598A (en) * | 1991-03-07 | 1998-06-16 | Virogenetics Corporation | Recombinant attenuated ALVAC canarypoxvirus expression vectors containing heterologous DNA segments encoding lentiviral gene products |
DK0592546T3 (en) * | 1991-06-14 | 2003-09-15 | Us Gov Health & Human Serv | Immunodeficiency virus recombinant poxvirus vaccine |
DE69229390T2 (en) * | 1991-08-26 | 1999-11-11 | Immuno Ag | Direct molecular cloning of a modified genome of a chordopox virus |
WO1995030018A2 (en) * | 1994-04-29 | 1995-11-09 | Immuno Aktiengesellschaft | Recombinant poxviruses with foreign polynucleotides in essential regions |
EP1683858A3 (en) | 1995-02-21 | 2006-08-02 | Cantab Pharmaceuticals Research Limited | Viral preparations, vectors, immunogens, and vaccines |
WO1997011714A1 (en) * | 1995-09-29 | 1997-04-03 | Immunex Corporation | Chemokine inhibitor |
AU2660397A (en) * | 1996-04-05 | 1997-10-29 | Board Of Regents, The University Of Texas System | Methods for producing soluble, biologically-active disulfide bond-containing eukaryotic proteins in bacterial cells |
US6083715A (en) * | 1997-06-09 | 2000-07-04 | Board Of Regents, The University Of Texas System | Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells |
US20030138454A1 (en) * | 1997-06-09 | 2003-07-24 | Oxxon Pharmaccines, Ltd. | Vaccination method |
GB9711957D0 (en) | 1997-06-09 | 1997-08-06 | Isis Innovation | Methods and reagents for vaccination |
MXPA00008352A (en) | 1998-02-27 | 2002-10-17 | Univ Pennsylvania | Vaccines, immunotherapeutics and methods for using the same. |
CN1196495C (en) | 1999-04-30 | 2005-04-13 | 宾夕法尼亚大学理事会 | Mutant human CD80 and copositions for and methods of making and using the same |
CA2408328C (en) * | 2000-05-10 | 2012-04-17 | Aventis Pasteur Limited | Immunogenic polypeptides encoded by mage minigenes and uses thereof |
CN1312171C (en) * | 2000-07-14 | 2007-04-25 | 宾夕法尼亚州立大学托管会 | DNA vaccines encoding HIV accessory proteins |
WO2002029088A2 (en) * | 2000-10-04 | 2002-04-11 | The Trustees Of The University Of Pennsylvania | Highly expressible genes |
US8216585B2 (en) | 2001-05-25 | 2012-07-10 | The Trustees Of The University Of Pennsylvania | Targeted particles and methods of using the same |
GB0118532D0 (en) * | 2001-07-30 | 2001-09-19 | Isis Innovation | Materials and methods relating to improved vaccination strategies |
CA2467486A1 (en) | 2001-11-30 | 2003-06-12 | Isis Innovation Limited | Vaccine |
WO2003072718A2 (en) * | 2002-02-22 | 2003-09-04 | Ivigene Corporation | In situ induced antigen technology (isiat) for identification of polynucleotides expressed during infection or colonization |
AU2003223527B2 (en) | 2002-04-09 | 2009-01-15 | Sanofi Pasteur Limited | Modified CEA nucleic acid and expression vectors |
PL372091A1 (en) * | 2002-05-16 | 2005-07-11 | Bavarian Nordic A/S | Expression of genes in modified vaccinia virus ankara by using the cowpox ati promoter |
NZ570709A (en) | 2003-06-13 | 2010-04-30 | Univ Pennsylvania | Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same |
US8008265B2 (en) | 2003-06-13 | 2011-08-30 | The Trustees Of The University Of Pennsylvania | Vaccines, immunotherapeutics and methods for using the same |
US20050175627A1 (en) * | 2003-09-24 | 2005-08-11 | Oxxon Therapeutics Ltd. | HIV pharmaccines |
KR101162970B1 (en) * | 2003-10-08 | 2012-07-12 | 테리온 바이오로직스, 인크. | Modified CEA/B7 vector |
US20080274140A1 (en) * | 2004-11-19 | 2008-11-06 | David B Weiner | Vaccines and Methods for Using the Same |
CA2636867C (en) * | 2006-01-13 | 2015-12-01 | The Trustees Of The University Of Pennsylvania | Vaccines and immunotherapeutics using codon optimized il-15 and methods for using the same |
EP1981905B1 (en) | 2006-01-16 | 2016-08-31 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Chlamydia vaccine |
KR101710981B1 (en) | 2006-07-28 | 2017-02-28 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | Improved vaccines and methods for using the same |
WO2009065546A1 (en) * | 2007-11-19 | 2009-05-28 | Transgene Sa | Poxviral oncolytic vectors |
US9687515B2 (en) | 2007-11-19 | 2017-06-27 | Transgene S.A. | Poxviral oncolytic vectors |
AU2009231598B2 (en) | 2008-04-04 | 2015-03-12 | The Trustees Of The University Of Pennsylvania | Vaccines and immunotherapeutics using IL-28 and compositions and methods of using the same |
WO2009124312A2 (en) * | 2008-04-04 | 2009-10-08 | The Trustees Of The University Of Pennsylvania | Consensus sequences of chikungunya viral proteins, nucleic acid molecules encoding the same, and compositions and methods for using the same |
US8921536B2 (en) | 2008-10-29 | 2014-12-30 | The Trustees Of The University Of Pennsylvania | HCV vaccines and methods for using the same |
US8829174B2 (en) | 2008-10-29 | 2014-09-09 | The Trustees Of The University Of Pennsylvania | HCV vaccines and methods for using the same |
CA2653478A1 (en) | 2009-01-23 | 2010-07-23 | Gregg Martin | Automated wash system for industrial vehicles |
US9050287B2 (en) | 2009-01-23 | 2015-06-09 | The Trustees Of The University Of Pennsylvania | Vaccines for human papilloma virus and methods for using the same |
WO2011032179A1 (en) | 2009-09-14 | 2011-03-17 | The Trustees Of The University Of Pennsylvania | Vaccines and immunotherapeutics comprising il-15 receptor alpha and/or nucleic acid molecules encoding the same, and methods for using the same |
KR101965337B1 (en) | 2009-11-02 | 2019-04-03 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | Foot and mouth disease virus (fmdv) consensus proteins, coding sequences therefor and vaccines made therefrom |
US8298820B2 (en) | 2010-01-26 | 2012-10-30 | The Trustees Of The University Of Pennsylvania | Influenza nucleic acid molecules and vaccines made therefrom |
WO2011097640A1 (en) | 2010-02-08 | 2011-08-11 | The Trustees Of The University Of Pennsylvania | Nucleic acid molecules encoding rantes, and compositions comprising and methods of using the same |
CN101935676A (en) * | 2010-08-20 | 2011-01-05 | 中国海洋大学 | Method for inducing in-vitro transformation of scallop tissue cells |
SI3536703T1 (en) | 2010-11-12 | 2022-04-29 | The Trustees Of The University Of Pennsylvania | Consensus prostate antigens, nucleic acid molecules encoding the same and uses thereof |
JP6099573B2 (en) | 2011-01-31 | 2017-03-22 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | Nucleic acid molecules encoding novel herpes antigens, vaccines containing them and methods of use thereof |
US9238679B2 (en) | 2011-02-11 | 2016-01-19 | The Trustees Of The University Of Pennslyvania | Nucleic acid molecule encoding hepatitis B virus core protein and surface antigen protein and vaccine comprising the same |
WO2012109668A1 (en) | 2011-02-11 | 2012-08-16 | The Trustees Of The University Of Pennsylvania | Nucleic acid molecule encoding hepatitis b virus core protein and vaccine comprising the same |
US9446114B2 (en) | 2011-07-11 | 2016-09-20 | Inovio Pharmaceuticals, Inc. | Cross-protective arenavirus vaccines and their method of use |
WO2013055326A2 (en) | 2011-10-12 | 2013-04-18 | The Trustees Of The University Of Pennsylvania | Vaccines for human papilloma virus and methods for using the same |
CA2851336C (en) | 2011-10-24 | 2021-01-12 | The Trustees Of The University Of Pennsylvania | Improved hcv vaccines and methods for using the same |
KR20220132652A (en) | 2011-12-12 | 2022-09-30 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | Compositions, comprising improved il-12 genetic constructs and vaccines, immunotherapeutics and methods of using the same |
JP6407028B2 (en) | 2011-12-12 | 2018-10-17 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | Protein containing MRSA PBP2a and fragments thereof, nucleic acid encoding the same, composition for preventing and treating MRSA infection and use thereof |
KR20140146651A (en) | 2012-04-10 | 2014-12-26 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | Human respiratory syncytial virus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same |
SG10201702292YA (en) * | 2012-09-21 | 2017-05-30 | Agency Science Tech & Res | Novel attenuated dengue virus strains for vaccine application |
EP3586870A1 (en) | 2013-03-12 | 2020-01-01 | The Trustees Of The University Of Pennsylvania | Improved vaccines for human papilloma virus and methods for using the same |
KR20150130284A (en) | 2013-03-15 | 2015-11-23 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | Cancer vaccines and methods of treatment using the same |
KR102276405B1 (en) | 2013-03-15 | 2021-07-12 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | Foot and mouth disease virus (fmdv) consensus proteins, coding sequences therefor and vaccines made therefrom |
JP7441169B2 (en) | 2017-12-13 | 2024-02-29 | イノビオ ファーマシューティカルズ,インコーポレイティド | Cancer vaccines targeting MUC16 and their use |
JP7352547B2 (en) | 2017-12-13 | 2023-09-28 | イノビオ ファーマシューティカルズ,インコーポレイティド | Cancer vaccines targeting mesothelin and their use |
BR112020011443A2 (en) | 2017-12-13 | 2020-12-01 | Inovio Pharmaceuticals, Inc. | nucleic acid molecule and its use, vector and its use, composition, protein and vaccine |
CN112779293A (en) * | 2021-01-27 | 2021-05-11 | 重庆市畜牧科学院 | Method for screening host cells of LacZ gene marker goat pox virus |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4703011A (en) * | 1985-11-12 | 1987-10-27 | Novagene, Inc. | Thymidine kinase deletion mutants of bovine herpesvirus-1 |
FR2604183B1 (en) * | 1986-09-23 | 1988-12-30 | Transgene Sa | DNA SEQUENCE, VECTORS, RECOMBINANT VIRUSES AND METHOD USING RECOMBINANT VACCINE VIRUSES CAPABLE OF MULTIPLYING IN CHO CELLS |
CA1341245C (en) * | 1988-01-12 | 2001-06-05 | F. Hoffmann-La Roche Ag | Recombinant vaccinia virus mva |
WO1989012103A1 (en) * | 1988-06-10 | 1989-12-14 | Applied Biotechnology, Inc. | Method of selecting for recombinant pox viruses |
GB2220941B (en) * | 1988-06-24 | 1991-09-11 | Nat Res Dev | Fowlpox virus non-essential regions |
US5225336A (en) * | 1989-03-08 | 1993-07-06 | Health Research Incorporated | Recombinant poxvirus host range selection system |
BR9106879A (en) * | 1990-09-25 | 1993-07-20 | Cantab Pharma Res | MUTUANT NON RETROVIRAL VIRUS, USE OF THE SAME, VACCINE AND PROCESS OF MANUFACTURING MUTANT UMVIRUS |
-
1990
- 1990-03-02 JP JP2505067A patent/JP3044062B2/en not_active Expired - Fee Related
- 1990-03-02 AT AT0902490A patent/AT400955B/en not_active IP Right Cessation
- 1990-03-02 CH CH3600/90A patent/CH682669A5/en not_active IP Right Cessation
- 1990-03-02 AU AU53320/90A patent/AU625584B2/en not_active Ceased
- 1990-03-02 NL NL9020389A patent/NL9020389A/en not_active Application Discontinuation
- 1990-03-02 DE DE4090351T patent/DE4090351T1/en not_active Withdrawn
- 1990-03-02 WO PCT/US1990/001268 patent/WO1990010693A1/en active Application Filing
- 1990-03-07 CA CA002011654A patent/CA2011654C/en not_active Expired - Fee Related
- 1990-03-07 IE IE81490A patent/IE62441B1/en not_active IP Right Cessation
- 1990-03-08 IT IT19623A patent/IT1239987B/en active IP Right Grant
- 1990-03-08 BE BE9000259A patent/BE1004212A5/en not_active IP Right Cessation
-
1991
- 1991-08-20 GB GB9117996A patent/GB2245272B/en not_active Expired - Fee Related
- 1991-09-04 LU LU88000A patent/LU88000A1/en unknown
- 1991-09-06 DK DK157091A patent/DK157091A/en not_active IP Right Cessation
-
1993
- 1993-08-05 US US08/102,702 patent/US5453364A/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
DE4090351T1 (en) | 1997-07-24 |
IE900814L (en) | 1990-09-08 |
LU88000A1 (en) | 1992-03-11 |
GB2245272B (en) | 1993-03-17 |
ATA902490A (en) | 1995-09-15 |
DK157091A (en) | 1991-09-26 |
AU5332090A (en) | 1990-10-09 |
AU625584B2 (en) | 1992-07-16 |
AT400955B (en) | 1996-05-28 |
NL9020389A (en) | 1991-12-02 |
BE1004212A5 (en) | 1992-10-13 |
IT9019623A0 (en) | 1990-03-08 |
JPH04503904A (en) | 1992-07-16 |
IE62441B1 (en) | 1995-02-08 |
WO1990010693A1 (en) | 1990-09-20 |
CA2011654C (en) | 1995-12-19 |
IT1239987B (en) | 1993-11-27 |
US5453364A (en) | 1995-09-26 |
DK157091D0 (en) | 1991-09-06 |
IT9019623A1 (en) | 1991-09-08 |
GB2245272A (en) | 1992-01-02 |
CH682669A5 (en) | 1993-10-29 |
GB9117996D0 (en) | 1991-10-09 |
JP3044062B2 (en) | 2000-05-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2011654A1 (en) | Recombinant poxvirus host range selection system | |
Thomsen et al. | Pseudorabies virus as a live virus vector for expression of foreign genes | |
AU585126B2 (en) | Recombinant herpes simplex viruses, vaccines and methods | |
DK0500917T3 (en) | Vaccines and methods based on recombinant herpes simplex viruses. | |
DE69024809T2 (en) | HERPES SIMPLEX VIRUS TYPE 1 MUTANT | |
ES8505719A1 (en) | Deletion mutant of a herpesvirus and vaccine containing said virus. | |
ATE73348T1 (en) | THYMIDINE KINASE DELETION MUTANTS OF BOVINE HERPESVIRUS-1, VACCINES AGAINST BOVINE RHINOTRACHEITIS CONTAINING THEM, AND METHODS FOR THEIR MANUFACTURE AND USE. | |
JP2008086326A (en) | Gene manipulation and expression using genomic element | |
ATE73349T1 (en) | HEPATITIS SURFACE ANTIGEN PARTICLE VACCINATION. | |
WO1994013812A3 (en) | Novel entomopoxvirus genes, proteins and methods of use thereof | |
DE3888290T2 (en) | Mutants of the infectious bovine rhinotracheitis virus, vaccines containing them, process for their preparation and their use. | |
EP0326127A3 (en) | Infectious bovine rhinotracheitis virus insertion mutants, vaccins containing same, and methods for the production and use of same | |
AU4334193A (en) | Infectious bovine rhinotracheitis virus mutants and vaccines | |
EP0994192A3 (en) | Transformation cassette for yeast | |
Mettenleiter et al. | Isolation of a viable herpesvirus (pseudorabies virus) mutant specifically lacking all four known nonessential glycoproteins | |
ATE360061T1 (en) | REPLICATION-DEFECTIVE MUTANTS OF HERPES VIRUS | |
AU3977997A (en) | Assembly-deficient herpesvirus vaccine | |
EP0811685A3 (en) | Human platelet-derived growth factor receptors | |
DE122007000004I1 (en) | Attenuated herpesviruses, herpesviruses containing foreign DNA encoding an amino acid sequence, and vaccines containing them | |
Goodman et al. | Identification, transfer, and characterization of cloned herpes simplex virus invasiveness regions | |
Vomvoyanni | Multigenic control of ribosomal properties associated with cycloheximide sensitivity in Neurospora crassa | |
EP0668356A3 (en) | Recombinant infectious bovine rhinotracheitis virus mutant, methods for the production of same, and vaccines containing the same | |
EP1415665A3 (en) | BHV5 mutants | |
WO2000008192A3 (en) | Herpesviral vectors for gene delivery | |
Aleksandrov et al. | Dry Live Aerosol Anthrax Vaccine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |